Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM F SYMMANS and NAOTO T UENO.
Connection Strength
1.304
-
Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. J Cancer. 2017; 8(6):1045-1052.
Score: 0.154
-
Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res. 2014 Oct 15; 20(20):5265-71.
Score: 0.128
-
Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. J Cancer. 2013; 4(9):697-702.
Score: 0.121
-
Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol. 2013 Dec; 10(12):711-9.
Score: 0.121
-
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40.
Score: 0.119
-
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95.
Score: 0.099
-
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
Score: 0.059
-
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
Score: 0.059
-
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
Score: 0.058
-
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
Score: 0.054
-
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
Score: 0.052
-
Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174.
Score: 0.044
-
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018 07; 77:121-129.
Score: 0.041
-
MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol. 2016 Apr; 29(4):330-46.
Score: 0.036
-
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol. 2014 Feb; 25(2):358-65.
Score: 0.030
-
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013 Nov 25; 15(6):R112.
Score: 0.030
-
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer. 2012 Mar 13; 106(6):1107-16.
Score: 0.027
-
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34.
Score: 0.027
-
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81.
Score: 0.025
-
B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther. 2006 Jun; 5(6):1593-601.
Score: 0.018